A Phase II Trial of Low-Dose Hypomethylating Agents in Patients with Low- or Intermediate-1-Risk MDS

The outcome of patients with lower-risk myelodysplastic syndrome (MDS) is heterogeneous. Whether hypomethylating agents (HMAs) can alter the natural history of this disease is unknown.

Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Nicholas Short, Guillermo Garcia-Manero, Guillermo Montalban-Bravo, Koji Sasaki, Mikkael Sekeres, Rami Komrokji, David Steensma, Amy DeZern, Gail Roboz, Tapan Kadia, Gautam Borthakur, Courtney DiNardo, Darla Miller, Zeev Estrov, Naveen Pemmaraju, Naval Da Source Type: research